CENP-A Nuclear Pattern Analysis for Cancer Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer diagnosis and treatment management face challenges in accurately identifying oncogenic transformations and predicting responses to therapies due to the variability in cancer malignancy and treatment effectiveness, leading to inefficient resource allocation and patient outcomes.
Innovation Solution
An in vitro method involving CENP-A labelling and nuclear pattern analysis, where tissue samples are labelled for CENP-A protein and examined for specific nuclear patterns indicative of oncogenic transformations, which can predict malignant lesions' responsiveness to radiotherapy, chemotherapy, and concurrent chemoradiation therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional cancer diagnosis methods are used, then basic cancer detection is possible, but accuracy in identifying oncogenic transformations and predicting treatment responses is insufficient
Solution Approach 1:
The invention changes the diagnostic parameter from conventional histological or molecular markers to CENP-A nuclear pattern analysis. By detecting specific nuclear patterns (peripheral vs. internal foci distribution) of CENP-A protein, the method achieves both accurate identification of oncogenic transformations and reliable prediction of treatment response, resolving the contradiction between diagnostic accuracy and prediction reliability.
2Adaptability or versatility
If multiple treatment options are provided without predictive markers, then treatment versatility is maintained, but resource allocation efficiency decreases due to ineffective therapies
Solution Approach 1:
The invention introduces a feedback mechanism through CENP-A nuclear pattern analysis that predicts treatment response before therapy administration. By classifying tumors as responsive or non-responsive based on nuclear pattern (peripheral foci distribution vs. internal foci), the system enables feedback-driven resource allocation, directing treatments only to patients likely to benefit, thus improving productivity while maintaining adaptability.
3Measurement precision
If detailed molecular analysis is performed to improve diagnosis, then measurement precision improves, but device complexity and procedural complexity increase
Solution Approach 1:
The invention extracts the essential diagnostic information from complex molecular profiles by focusing specifically on CENP-A nuclear pattern morphology. Instead of analyzing multiple genes and proteins simultaneously, the method isolates and analyzes the nuclear distribution pattern of a single protein (CENP-A), simplifying the analytical procedure while maintaining high precision for detecting oncogenic transformations.
Data Source
AI summary
Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody-producing cells. The hybrid lines derived are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice.Spleens from mice immunized against sheep red blood cells (SRBC) were fused to an 8-azaguanine-resistant clone (X63-Ag8) of MOPC 21 myeloma. Over 50% of the derived hybrid lines produce and secrete immunoglobulins different from the MOPC 21 myeloma. About 10% of the hybrid lines exhibit anti-SRBC activity. The high proportion of antibody-producing hybrids suggests that the fusion involves a restricted fraction of the spleen cell population, probably cells committed to antibody production.In order to avoid the presence of the MOPC 21 heavy chain in the specific hybrids, another myeloma cell line (NSI/Ag4-1) has been used. This is a nonsecreting variant of the MOPC 21 myeloma which does not express heavy chains.Three anti-SRBC (probably of the μ, γ2b and γ1 classes, respectively) and two anti-2,4,6-trinitrophenyl (of the μ class antibody-producing hybrids have been repeatedly cloned. By random selection and by selection of specific clones according to their lytic activity (clone plaque selection), a number of different lines have been constructed. Such lines express different combinations of the four possible chains of each hybrid line: the myeloma γ and k chains and the specific antibody heavy and light chains. In three cases (Sp1, Sp2 and Sp7) it is shown that only the specific H and L combination has activity and that the myeloma chains are unable to substitute for them. In most cases lines have been derived which no longer express the MOPC 21 chains but only the specific antibody chains.